Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)

NCT04621188 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

54

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer Metastatic

Interventions

DRUG: Lorlatinib

Sponsor

Intergroupe Francophone de Cancerologie Thoracique